Literature DB >> 12930923

Hematopoietic growth factors and the future of therapeutic research on acute myeloid leukemia.

Charles A Schiffer1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12930923     DOI： 10.1056/NEJMp030076

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

Review 1.  Acute myeloid leukemia: advancing clinical trials and promising therapeutics.

Authors:  Naval Daver; Jorge Cortes; Hagop Kantarjian; Farhad Ravandi
Journal:  Expert Rev Hematol       Date:  2016-03-17       Impact factor: 2.929

Review 2.  FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?

Authors:  Naveen Pemmaraju; Hagop Kantarjian; Farhad Ravandi; Jorge Cortes
Journal:  Cancer       Date:  2011-02-11       Impact factor: 6.860

3.  Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study.

Authors:  Sergio Amadori; Stefan Suciu; Ulrich Jehn; Roberto Stasi; Xavier Thomas; Jean-Pierre Marie; Petra Muus; Francois Lefrère; Zwi Berneman; George Fillet; Claudio Denzlinger; Roel Willemze; Pietro Leoni; Giuseppe Leone; Marco Casini; Francesco Ricciuti; Marco Vignetti; Filip Beeldens; Franco Mandelli; Theo De Witte
Journal:  Blood       Date:  2005-03-10       Impact factor: 22.113

4.  miR-338-3p Plays a Significant Role in Casticin-Induced Suppression of Acute Myeloid Leukemia via Targeting PI3K/Akt Pathway.

Authors:  Kewei Yu; Juan Wang; Junhui Hou; Lei Zhang; Hui Liang
Journal:  Biomed Res Int       Date:  2022-06-18       Impact factor: 3.246

5.  Trial Watch: Immunostimulatory cytokines.

Authors:  Erika Vacchelli; Lorenzo Galluzzi; Alexander Eggermont; Jerome Galon; Eric Tartour; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2012-07-01       Impact factor: 8.110

6.  Design, Synthesis, In Silico Studies and Inhibitory Activity towards Bcr-Abl, BTK and FLT3-ITD of New 2,6,9-Trisubstituted Purine Derivatives as Potential Agents for the Treatment of Leukaemia.

Authors:  Jeanluc Bertrand; Hana Dostálová; Vladimír Kryštof; Radek Jorda; Thalía Delgado; Alejandro Castro-Alvarez; Jaime Mella; David Cabezas; Mario Faúndez; Christian Espinosa-Bustos; Cristian O Salas
Journal:  Pharmaceutics       Date:  2022-06-17       Impact factor: 6.525
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.